Akzo Nobel N.v.

N.v. Organon

Johannes Bernardus Maria Rewinkel

Constant Adriaan Anton Van Boeckel

Philippus Johannes Marie Van Galen

Brigitte Johanna Bernita Folmer

Cornelis Marius Timmers

Hemen Ibrahim

Maria Lourdes Ollero

Pedro Harold Han Hermkens

Paolo Giovanni Martino Conti

Hans Lucas

Paul Peter Marie Antonius Dols

Johannes Antonius Maria Hamersma

Maria Lourdes Ollero-Ollero

The present invention provides new progesterone receptor modulators which are dibenzo[b,f]pyrido[1,2-d]oxazepine-2-amines or dibenzo[b,f]prido[1,2-d]thiazepine-2-amines, and uses thereof.

Progesterone receptor modulators

The present invention provides new progesterone receptor modulators which are (cis)-8-fluorodibenzo[b,f]pyrido[1,2-d]oxazepine-1-amine compounds and uses thereof.

The present invention provides compounds according to general Formula (I), a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a prodrug thereof. More particularly, the present invention provides high affinity non-steroidal compounds which are agonists, partial agonists or antagonists of the progesterone receptor.

Non-steroidal progesterone receptor modulators

The subject invention provides a compound according to Formula I, wherein each of the substituents is given the definition as set forth in the specification and claims, or a pharmaceutically acceptable salt and/or hydrate form and/or prodrug thereof.

A serine protease inhibitor having the formula (I),in which

Serine protease inhibitor

The present invention relates to antithrombotic compounds comprising the group Q, Q having formula (I), wherein the substructure (i) is a structure selected from (a, b and c), wherein X is O or S; X&prime; being independently CH or N; and m is 0, 1, 2 or 3; wherein the group Q is bound through an oxygen atom or an optionally substituted nitrogen or carbon atom, or a pharmaceutically acceptable salt thereof or a prodrug thereof. The compounds of the invention are therapeutically active and in particular are antithrombotic agents.

Heterocyclic derivatives and their use as antithrombotic agents

Thrombin inhibitors comprising an aminoisoquinoline group

The present invention relates to heterocyclic antithrombotic compounds comprising a compound of the Formula I, wherein X&prime; is independently CH or N, and m is 0, 1, 2 or 3, or a pharmaceutically acceptable salt or prodrug thereof.

The present invention relates to therapeutically active antithrombotic compounds.

Growing community of inventors

Oss, Netherlands

Johannes Bernardus Maria Rewinkel